Cooperation Prospects Strategic partnership opportunities with Lilly through co-stimulatory bispecific antibody programs in solid tumors. Rondo’s CD28 platform paired with a pharma collaborator could accelerate development timelines and share commercialization expertise.

Clinical Focus Strong emphasis on next-generation immuno-oncology and bispecific antibodies for solid tumors presents a clear target for partnerships, licensing, or co-development deals with biotech and larger pharma seeking novel modalities.

Leadership Signals Recent additions to leadership and scientific advisory board including seasoned biotech executives and renowned scientists suggest increasing credibility and readiness for larger-scale partnerships and investments.

Funding & Growth Series A funding of 67 million and current revenue range indicate a financially active company likely open to collaboration agreements, grants, or milestone-driven deals to de-risk and scale programs.

Market Readiness Focus on tumor-targeting bispecifics with broad therapeutic windows aligns with market demand for safer, more effective oncology therapies, offering opportunities for early-stage co-development, sponsored research, or technology licensing.